Date: 2022	<u>/03/01</u>
Your Name:	Jia Hou
Manuscript Titl	e: Proscillaridin A induces mitochondrial damage and autophagy in pancreatic cancer and reduce
the stability of	SMAD4 in Panc-1
Manuscript nui	mber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>√</u> None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	√ None √ None	
O	testimony	None	
7	Support for attending meetings and/or travel	<u>√</u> None	
8	Patents planned, issued or pending	_√_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>√</u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>√</u> None	
11	Stock or stock options	<u>√</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_√_None	
13	Other financial or non- financial interests	None	

The author has no conflicts	of interests to declare.	

Please place an "X" next to the following statement to indicate your agreement:

Date:	2022/0	<u>8/01</u>
Your Nan	ne:	Ning Kang
Manuscri	pt Title:	Proscillaridin A induces mitochondrial damage and autophagy in pancreatic cancer and reduces
the stabil	ity of SN	IAD4 in Panc-1
Manuscri	pt numb	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>√</u> None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>√</u> None	
3	Royalties or licenses	_√_None	
4	Consulting fees	_√_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	√ None √ None	
O	testimony	None	
7	Support for attending meetings and/or travel	<u>√</u> None	
8	Patents planned, issued or pending	_√_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>√</u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>√</u> None	
11	Stock or stock options	<u>√</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_√_None	
13	Other financial or non- financial interests	None	

The author has no conflicts	of interests to declare.	

Please place an "X" next to the following statement to indicate your agreement:

Date:	2022/0	<u>3/01 </u>	
Your Nar	ne:	Nannan Liu	
Manuscr	ipt Title:	Proscillaridin A induces mitochondrial damage and autophagy in pancreati	ic cancer and reduces
the stabi	lity of SN	MAD4 in Panc-1	
Manuscr	ipt numb	per (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_√_None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	√ None √ None	
O	testimony	None	
7	Support for attending meetings and/or travel	<u>√</u> None	
8	Patents planned, issued or pending	_√_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>√</u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>√</u> None	
11	Stock or stock options	<u>√</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_√_None	
13	Other financial or non- financial interests	None	

The author has no conflicts	of interests to declare.	

Please place an "X" next to the following statement to indicate your agreement:

Date:202	<u>2/03/01</u>
Your Name:	Dan Tan
Manuscript Ti	tle: Proscillaridin A induces mitochondrial damage and autophagy in pancreatic cancer and reduces
the stability o	f SMAD4 in Panc-1
Manuscript nu	ımber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	<u>√</u> None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>√</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	√ None √ None	
O	testimony	None	
7	Support for attending meetings and/or travel	<u>√</u> None	
8	Patents planned, issued or pending	_√_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>√</u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>√</u> None	
11	Stock or stock options	<u>√</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_√_None	
13	Other financial or non- financial interests	None	

The author has no conflicts of interests to declare.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 2022	<u>2/03/01</u>
Your Name:	Si Zhang
Manuscript Tit	le: Proscillaridin A induces mitochondrial damage and autophagy in pancreatic cancer and reduce
the stability of	SMAD4 in Panc-1
Manuscript nu	mber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_√_None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	√ None √ None	
O	testimony	None	
7	Support for attending meetings and/or travel	<u>√</u> None	
8	Patents planned, issued or pending	_√_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>√</u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>√</u> None	
11	Stock or stock options	<u>√</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_√_None	
13	Other financial or non- financial interests	None	

The author has no conflicts of interests to declare.		

Please place an "X" next to the following statement to indicate your agreement:

Date:202	<u>2/03/01</u>
Your Name:	Jing Liu
Manuscript Ti	tle: Proscillaridin A induces mitochondrial damage and autophagy in pancreatic cancer and reduces
the stability o	f SMAD4 in Panc-1
Manuscript nu	ımber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>√</u> None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>√</u> None	
3	Royalties or licenses	None	
4	Consulting fees	_√_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	√ None √ None	
O	testimony	None	
7	Support for attending meetings and/or travel	<u>√</u> None	
8	Patents planned, issued or pending	_√_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>√</u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>√</u> None	
11	Stock or stock options	<u>√</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_√_None	
13	Other financial or non- financial interests	None	

The author has no conflicts of interests to declare.		

Please place an "X" next to the following statement to indicate your agreement:

Date:	2022/0	3/01	
Your Nam	e:	Youhua Xie	
Manuscri	pt Title:_	Proscillaridin A	induces mitochondrial damage and autophagy in pancreatic cancer and reduces
the stabili	ity of SN	IAD4 in Panc-1	_
Manuscrii	ot numb	er (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)				
	Time frame: Since the initial planning of the work						
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>√</u> None					
	Time frame: past 36 months						
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>√</u> None					
3	Royalties or licenses	_√_None					
4	Consulting fees	_√_None					

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	√ None √ None	
O	testimony	None	
7	Support for attending meetings and/or travel	<u>√</u> None	
8	Patents planned, issued or pending	_√_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>√</u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>√</u> None	
11	Stock or stock options	<u>√</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_√_None	
13	Other financial or non- financial interests	None	

The author has no conflicts of interests to declare.			

Please place an "X" next to the following statement to indicate your agreement: